No Data
No Data
Abbisko Cayman Unit's Cancer Drug To Be Clinically Tested in Combination With Shanghai Allist's Furmonertinib
Abbisko Cayman (HKG:2256) unit Abbisko Therapeutics said its investigational non-small cell lung cancer drug ABSK043 would be clinically tested in combination with Furmonertinib Mesilate Tablets, acco
Heyu-B (02256.HK): Carrying out clinical research on ABSK043 combined with vometinib mesylate tablets to treat advanced non-small cell lung cancer
On May 9, Ge Longhui (02256.HK) announced that ABSK043, an oral small molecule PD-L1 inhibitor developed by it, will soon conduct clinical research on combination treatment for advanced non-small cell lung cancer with vometinib mesylate tablets (trade name: Avsha, “vometinib”) independently developed by Allis (688578.SH).
Alice (688578.SH): Net profit in 2023 increased 393.54% year-on-year, and plans to pay 10 to 4 yuan
On April 25, Ge Longhui (688578.SH) released its 2023 annual report. During the reporting period, the company achieved operating income of 2,018 billion yuan, an increase of 155.14%; net profit attributable to shareholders of listed companies was 644 million yuan, an increase of 393.54%; net profit attributable to shareholders of listed companies deducted non-recurring profit and loss of 606 million yuan, an increase of 663.70% year on year; basic income per share was 1.43 yuan/share. It is proposed to distribute a cash dividend of $4.00 (tax included) for every 10 shares.
Some Confidence Is Lacking In Shanghai Allist Pharmaceuticals Co., Ltd.'s (SHSE:688578) P/E
Shanghai Allist Pharmaceuticals Co., Ltd.'s (SHSE:688578) price-to-earnings (or "P/E") ratio of 33.3x might make it look like a sell right now compared to the market in China, where around half of th
Is Shanghai Allist Pharmaceuticals Co., Ltd.'s (SHSE:688578) Latest Stock Performance A Reflection Of Its Financial Health?
Most readers would already be aware that Shanghai Allist Pharmaceuticals' (SHSE:688578) stock increased significantly by 15% over the past three months. Given the company's impressive performance, w
Alice (688578.SH): AST2169 liposome for injection obtained approval notice for drug clinical trials
Gelonghui (688578.SH) announced on March 13, that the company recently received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration. The phase I clinical study on the safety, tolerability, pharmacokinetics and initial efficacy of the self-developed AST2169 liposome for injection (known as “AST2169”) in patients with advanced solid tumors with KRAS G12D mutations was approved for drug clinical trials. AST2169 is a KRAS G12D selective inhibitor with global intellectual property rights independently developed by the company. KRAS G12D mutation
No Data